IgG antibody response against Plasmodium falciparum aminopeptidase 1 antigen in Gabonese children living in Makokou and Franceville

Abstract

The search for novel chemical classes of anti-malarial compounds to cope with the current state of chemoresistance of malaria parasites has led to the identification of Plasmodium falciparum aminopeptidase 1 (PfA-M1) as a new therapeutic target. PfA-M1, known to be involved in the hemoglobin digestion cascade which helps to provide most of the amino acids necessary to the parasite's metabolism, is currently considered as a promising target for anti-malarial chemotherapy. However, its immunogenic properties have not yet been tested in the Gabonese population. In Gabon, the prevalence of malaria remains three times higher in semi-urban areas (60·12%) than in urban areas (17·06%). We show that malaria-specific PfA-M1 antibodies are present in children and increase with the level of infection. Children living in semi-urban areas have higher anti-PfA-M1 antibody titers (0·14 ± 0·02 AU) than those living in urban areas (0·08 ± 0·02 AU, P = 0·03), and their antibody titers increase with age (P < 0·0001). Moreover, anti-PfA-M1 antibody titers decrease in children with hyperparasitemia (0·027 ± 0·055 AU) but they remain high in children with low parasite density (0·21 ± 0·034 AU, P = 0·034). In conclusion, our results suggest that malariaspecific PfA-M1 antibodies may play an important role in the immune response of the host against P. falciparum in Gabonese children. Further studies on the role of PfA-M1 during anemia are needed.

Characterization of a Trichinella spiralis aminopeptidase and its participation in invasion, development and fecundity

“…In the bovine filaria Setaria cervi, this enzyme participated in parasite feeding, digestion, cuticle remodeling, egg hatching and embryogenesis [64]. Recent studies showed that Plasmodium falciparum aminopeptidase 1 (PfA-M1) is involved in the hemoglobin digestion cascade that provides most of the amino acids necessary to the parasite's metabolism, it is regarded as a promising new therapeutic target [65]. The mutation of Caenorhabditis elegans aminopeptidase 1 (ANP-1) induced small body size in the L4/young adult stage of C. elegans.…”